A pilot study on developing mucosal vaccine against alveolar echinococcosis (AE) using recombinant tetraspanin 3: Vaccine efficacy and immunology.

BACKGROUND: We have previously evaluated the vaccine efficacies of seven tetraspanins of Echinococcus multilocularis (Em-TSP1-7) against alveolar echinococcosis (AE) by subcutaneous (s.c.) administration with Freund's adjuvant. Over 85% of liver cyst lesion number reductions (CLNR) were achieve...

Full description

Bibliographic Details
Main Authors: Zhisheng Dang, Kinpei Yagi, Yuzaburo Oku, Hirokazu Kouguchi, Kiichi Kajino, Jun Matsumoto, Ryo Nakao, Hiroyuki Wakaguri, Atsushi Toyoda, Hong Yin, Chihiro Sugimoto
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS Neglected Tropical Diseases
Online Access:http://europepmc.org/articles/PMC3313938?pdf=render
id doaj-41d65f8bb86543a8816c71a06ddc422c
record_format Article
spelling doaj-41d65f8bb86543a8816c71a06ddc422c2020-11-25T01:32:49ZengPublic Library of Science (PLoS)PLoS Neglected Tropical Diseases1935-27352012-01-0163e157010.1371/journal.pntd.0001570A pilot study on developing mucosal vaccine against alveolar echinococcosis (AE) using recombinant tetraspanin 3: Vaccine efficacy and immunology.Zhisheng DangKinpei YagiYuzaburo OkuHirokazu KouguchiKiichi KajinoJun MatsumotoRyo NakaoHiroyuki WakaguriAtsushi ToyodaHong YinChihiro SugimotoBACKGROUND: We have previously evaluated the vaccine efficacies of seven tetraspanins of Echinococcus multilocularis (Em-TSP1-7) against alveolar echinococcosis (AE) by subcutaneous (s.c.) administration with Freund's adjuvant. Over 85% of liver cyst lesion number reductions (CLNR) were achieved by recombinant Em-TSP1 (rEm-TSP1) and -TSP3 (rEm-TSP3). However, to develop an efficient and safe human vaccine, the efficacy of TSP mucosal vaccines must be thoroughly evaluated. METHODOLOGY/PRINCIPAL FINDINGS: rEm-TSP1 and -TSP3 along with nontoxic CpG ODN (CpG oligodeoxynucleotides) adjuvant were intranasally (i.n.) immunized to BALB/c mice and their vaccine efficacies were evaluated by counting liver CLNR (experiment I). 37.1% (p < 0.05) and 62.1% (p < 0.001) of CLNR were achieved by these two proteins, respectively. To study the protection-associated immune responses induced by rEm-TSP3 via different immunization routes (i.n. administration with CpG or s.c. immunization with Freund's adjuvant), the systemic and mucosal antibody responses were detected by ELISA (experiment II). S.c. and i.n. administration of rEm-TSP3 achieved 81.9% (p < 0.001) and 62.8% (p < 0.01) CLNR in the liver, respectively. Both the immunization routes evoked strong serum IgG, IgG1 and IgG2α responses; i.n. immunization induced significantly higher IgA responses in nasal cavity and intestine compared with s.c. immunization (p < 0.001). Both immunization routes induced extremely strong liver IgA antibody responses (p < 0.001). The Th1 and Th2 cell responses were assessed by examining the IgG1/IgG2α ratio at two and three weeks post-immunization. S.c. immunization resulted in a reduction in the IgG1/IgG2α ratio (Th1 tendency), whereas i.n. immunization caused a shift from Th1 to Th2. Moreover, immunohistochemistry showed that Em-TSP1 and -TSP3 were extensively located on the surface of E. multilocularis cysts, protoscoleces and adult worms with additional expression of Em-TSP3 in the inner part of protoscoleces and oncospheres. CONCLUSIONS: Our study indicated that i.n. administration of rEm-TSP3 with CpG is able to induce both systemic and local immune responses and thus provides significant protection against AE.http://europepmc.org/articles/PMC3313938?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Zhisheng Dang
Kinpei Yagi
Yuzaburo Oku
Hirokazu Kouguchi
Kiichi Kajino
Jun Matsumoto
Ryo Nakao
Hiroyuki Wakaguri
Atsushi Toyoda
Hong Yin
Chihiro Sugimoto
spellingShingle Zhisheng Dang
Kinpei Yagi
Yuzaburo Oku
Hirokazu Kouguchi
Kiichi Kajino
Jun Matsumoto
Ryo Nakao
Hiroyuki Wakaguri
Atsushi Toyoda
Hong Yin
Chihiro Sugimoto
A pilot study on developing mucosal vaccine against alveolar echinococcosis (AE) using recombinant tetraspanin 3: Vaccine efficacy and immunology.
PLoS Neglected Tropical Diseases
author_facet Zhisheng Dang
Kinpei Yagi
Yuzaburo Oku
Hirokazu Kouguchi
Kiichi Kajino
Jun Matsumoto
Ryo Nakao
Hiroyuki Wakaguri
Atsushi Toyoda
Hong Yin
Chihiro Sugimoto
author_sort Zhisheng Dang
title A pilot study on developing mucosal vaccine against alveolar echinococcosis (AE) using recombinant tetraspanin 3: Vaccine efficacy and immunology.
title_short A pilot study on developing mucosal vaccine against alveolar echinococcosis (AE) using recombinant tetraspanin 3: Vaccine efficacy and immunology.
title_full A pilot study on developing mucosal vaccine against alveolar echinococcosis (AE) using recombinant tetraspanin 3: Vaccine efficacy and immunology.
title_fullStr A pilot study on developing mucosal vaccine against alveolar echinococcosis (AE) using recombinant tetraspanin 3: Vaccine efficacy and immunology.
title_full_unstemmed A pilot study on developing mucosal vaccine against alveolar echinococcosis (AE) using recombinant tetraspanin 3: Vaccine efficacy and immunology.
title_sort pilot study on developing mucosal vaccine against alveolar echinococcosis (ae) using recombinant tetraspanin 3: vaccine efficacy and immunology.
publisher Public Library of Science (PLoS)
series PLoS Neglected Tropical Diseases
issn 1935-2735
publishDate 2012-01-01
description BACKGROUND: We have previously evaluated the vaccine efficacies of seven tetraspanins of Echinococcus multilocularis (Em-TSP1-7) against alveolar echinococcosis (AE) by subcutaneous (s.c.) administration with Freund's adjuvant. Over 85% of liver cyst lesion number reductions (CLNR) were achieved by recombinant Em-TSP1 (rEm-TSP1) and -TSP3 (rEm-TSP3). However, to develop an efficient and safe human vaccine, the efficacy of TSP mucosal vaccines must be thoroughly evaluated. METHODOLOGY/PRINCIPAL FINDINGS: rEm-TSP1 and -TSP3 along with nontoxic CpG ODN (CpG oligodeoxynucleotides) adjuvant were intranasally (i.n.) immunized to BALB/c mice and their vaccine efficacies were evaluated by counting liver CLNR (experiment I). 37.1% (p < 0.05) and 62.1% (p < 0.001) of CLNR were achieved by these two proteins, respectively. To study the protection-associated immune responses induced by rEm-TSP3 via different immunization routes (i.n. administration with CpG or s.c. immunization with Freund's adjuvant), the systemic and mucosal antibody responses were detected by ELISA (experiment II). S.c. and i.n. administration of rEm-TSP3 achieved 81.9% (p < 0.001) and 62.8% (p < 0.01) CLNR in the liver, respectively. Both the immunization routes evoked strong serum IgG, IgG1 and IgG2α responses; i.n. immunization induced significantly higher IgA responses in nasal cavity and intestine compared with s.c. immunization (p < 0.001). Both immunization routes induced extremely strong liver IgA antibody responses (p < 0.001). The Th1 and Th2 cell responses were assessed by examining the IgG1/IgG2α ratio at two and three weeks post-immunization. S.c. immunization resulted in a reduction in the IgG1/IgG2α ratio (Th1 tendency), whereas i.n. immunization caused a shift from Th1 to Th2. Moreover, immunohistochemistry showed that Em-TSP1 and -TSP3 were extensively located on the surface of E. multilocularis cysts, protoscoleces and adult worms with additional expression of Em-TSP3 in the inner part of protoscoleces and oncospheres. CONCLUSIONS: Our study indicated that i.n. administration of rEm-TSP3 with CpG is able to induce both systemic and local immune responses and thus provides significant protection against AE.
url http://europepmc.org/articles/PMC3313938?pdf=render
work_keys_str_mv AT zhishengdang apilotstudyondevelopingmucosalvaccineagainstalveolarechinococcosisaeusingrecombinanttetraspanin3vaccineefficacyandimmunology
AT kinpeiyagi apilotstudyondevelopingmucosalvaccineagainstalveolarechinococcosisaeusingrecombinanttetraspanin3vaccineefficacyandimmunology
AT yuzaburooku apilotstudyondevelopingmucosalvaccineagainstalveolarechinococcosisaeusingrecombinanttetraspanin3vaccineefficacyandimmunology
AT hirokazukouguchi apilotstudyondevelopingmucosalvaccineagainstalveolarechinococcosisaeusingrecombinanttetraspanin3vaccineefficacyandimmunology
AT kiichikajino apilotstudyondevelopingmucosalvaccineagainstalveolarechinococcosisaeusingrecombinanttetraspanin3vaccineefficacyandimmunology
AT junmatsumoto apilotstudyondevelopingmucosalvaccineagainstalveolarechinococcosisaeusingrecombinanttetraspanin3vaccineefficacyandimmunology
AT ryonakao apilotstudyondevelopingmucosalvaccineagainstalveolarechinococcosisaeusingrecombinanttetraspanin3vaccineefficacyandimmunology
AT hiroyukiwakaguri apilotstudyondevelopingmucosalvaccineagainstalveolarechinococcosisaeusingrecombinanttetraspanin3vaccineefficacyandimmunology
AT atsushitoyoda apilotstudyondevelopingmucosalvaccineagainstalveolarechinococcosisaeusingrecombinanttetraspanin3vaccineefficacyandimmunology
AT hongyin apilotstudyondevelopingmucosalvaccineagainstalveolarechinococcosisaeusingrecombinanttetraspanin3vaccineefficacyandimmunology
AT chihirosugimoto apilotstudyondevelopingmucosalvaccineagainstalveolarechinococcosisaeusingrecombinanttetraspanin3vaccineefficacyandimmunology
AT zhishengdang pilotstudyondevelopingmucosalvaccineagainstalveolarechinococcosisaeusingrecombinanttetraspanin3vaccineefficacyandimmunology
AT kinpeiyagi pilotstudyondevelopingmucosalvaccineagainstalveolarechinococcosisaeusingrecombinanttetraspanin3vaccineefficacyandimmunology
AT yuzaburooku pilotstudyondevelopingmucosalvaccineagainstalveolarechinococcosisaeusingrecombinanttetraspanin3vaccineefficacyandimmunology
AT hirokazukouguchi pilotstudyondevelopingmucosalvaccineagainstalveolarechinococcosisaeusingrecombinanttetraspanin3vaccineefficacyandimmunology
AT kiichikajino pilotstudyondevelopingmucosalvaccineagainstalveolarechinococcosisaeusingrecombinanttetraspanin3vaccineefficacyandimmunology
AT junmatsumoto pilotstudyondevelopingmucosalvaccineagainstalveolarechinococcosisaeusingrecombinanttetraspanin3vaccineefficacyandimmunology
AT ryonakao pilotstudyondevelopingmucosalvaccineagainstalveolarechinococcosisaeusingrecombinanttetraspanin3vaccineefficacyandimmunology
AT hiroyukiwakaguri pilotstudyondevelopingmucosalvaccineagainstalveolarechinococcosisaeusingrecombinanttetraspanin3vaccineefficacyandimmunology
AT atsushitoyoda pilotstudyondevelopingmucosalvaccineagainstalveolarechinococcosisaeusingrecombinanttetraspanin3vaccineefficacyandimmunology
AT hongyin pilotstudyondevelopingmucosalvaccineagainstalveolarechinococcosisaeusingrecombinanttetraspanin3vaccineefficacyandimmunology
AT chihirosugimoto pilotstudyondevelopingmucosalvaccineagainstalveolarechinococcosisaeusingrecombinanttetraspanin3vaccineefficacyandimmunology
_version_ 1725079605031731200